Jia Liu: Global Experts at Inaugural ESMO TAT Asia 2025 in Hong Kong
Jia Liu, Translational Lead, Early Phase Drug Development at The Kinghorn Cancer Centre , shared post on LinkedIn:
“Last week I was honoured to join global drug development experts as faculty at the inaugural ESMOTATAsia25 meeting in Hong Kong, which brought together clinicians, researchers, investigators, regulatory experts and sponsors from the Asia Pacific region to discuss exciting developments in early phase clinical trials including AI, cell therapy, radioligands. PROs and opportunities/challenges in drug development in our region.
I spoke on dose optimisation in the complex situation of combination therapies, a challenge we face given the exploding number of agents in development – how to rationalise combining them safely and to ensure any additional toxicity is worth the efficacy gain?
- Helpful resources include TimothyYap’s article in AACR Journals Clinical Cancer Research on Project Optimus recommendations for combination therapy.
- And FDA’s guidance on combination therapies published only last week.
All webcasts and slides from the meeting now accessible at ESMO – European Society for Medical Oncology OncologyPro.
ESMO leadership George Papadopoulos, fabrice andre, Giuseppe Curigliano and the amazing organizing committee Brigette B.Y. Ma, Byoung Chul Cho and YashushiGoto on an excellent program and warm hospitality despite an unexpected visitor… TyphoonWhipa … which only gave us an excuse to discuss extra collaborations and eat more because we were stuck in the hotel
Hope to see you all at ESMO25 and ESMOTATAsia26.”
More posts featuring Jia Liu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023